BCR-RET, Active(R02-19EG)
FOR BULK ORDER REQUESTS PLEASE CONTACT US
Description :Recombinant human BCR-RET, the fusion protein [BCR (1-426)-RET (713-end)], was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.
Species :Human
Tag :GST tag
Expression System:Sf9 insect cells using baculovirus
Sequence :1-426 (BCR) - 713-end (RET)
Genbank Number :BC066122
Genbank Number 2 :NM_020630
Specific Activity :Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.
Purity :Sample Purity Data. For specific information on a given lot, see related technical data sheet.
Storage, Stability and Shipping :Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Applications :Kinase Assay
Molecular Weight :140 kDa
Gene Aliases :BCR: ALL, CML, PHL, BCR1, D22S11, D22S662, FLJ16453
RET: CDHF12, RET51, PTC, RET-ELE1; RET/PTC2
Scientific Background :BCR-RET is a chimaeric fusion of BCR and RET genes generated by a balanced translocation of genes from t(10;22)(q11;q11) and this leads to aberrant activation of RET activity which can transform hematopoietic cells and skew the hematopoietic differentiation program towards the monocytic/macrophage lineage (1). The BCR-RET fusion is frequently found in chronic myelomonocytic leukemia (CMML) cases. The RET fusion genes seem to constitutively mimic the same signaling pathway as RAS mutations frequently involved in CMML.
References :
1.Ballerini, P. et al: RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation. Leukemia. 2012 Nov;26(11):2384-9.
Product Sheets (By Lot #) :
Research Areas :Cancer, Receptor Tyrosine Kinases, Cancer, Receptor Tyrosine Kinases